Spots Global Cancer Trial Database for Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Monteris AutoLITT™ FIM Safety Trial for Recurrent/Progressive Brain Tumors
Official Title: AutoLITT™ FIM Trial - A Prospective First-In-Man (FIM) Safety Trial of the AutoLITT Laser Treatment of Recurrent/Progressive Brain Tumors
Study ID: NCT00747253
Interventions
Study Description
Brief Summary: The main purpose of this study is to evaluate the safety and performance of the AutoLITT system for the treatment of recurrent/progressive glioblastoma multiforme tumors (GBM).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
Cleveland Clinic Foundation, 9500 Euclid Ave, Cleveland, Ohio, United States
Contact Details
Name: Gene Barnett, MD
Affiliation: The Cleveland Clinic
Role: PRINCIPAL_INVESTIGATOR
Name: Andrew Sloan, MD
Affiliation: University Hospitals Cleveland Medical Center
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
